For the quarter ending 2025-09-30, BICX had $175,816 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -808,505 | -2,229,040 |
| Change in fair value of royalty liability | - | -31,324 |
| Depreciation and amortization | 168,807 | - |
| Amortization of discount on royalty obligation | 121,774 | 233,888 |
| Amortization of debt discount | 53,861 | - |
| Amortization of right-of-use asset | 10,112 | 19,629 |
| Imputed interest for the related party notes | 9,253 | 18,814 |
| Loss on settlement of debt | 0 | -187,514 |
| Change in fair value of upfront purchase price liability | 1,785 | 4,894 |
| Change in fair value of royalty liability | 31,324 | - |
| Fair value of options issued | 81,874 | - |
| Other income | 0 | 0 |
| Stock based compensation | -65,813 | 307,159 |
| Accounts receivable | 143,200 | 51,242 |
| Grant receivable | -915,243 | 153,728 |
| Prepaid expenses | -13,880 | 47,081 |
| Accounts payable and accrued expenses | 868,743 | 950,355 |
| Depreciation and amortization | - | 96,820 |
| Deposits | 0 | 0 |
| Amortization of debt discount | - | 52,522 |
| Lease liability | -10,112 | -19,629 |
| Upfront purchase price liability | -158,007 | -155,673 |
| Deferred revenue | 0 | 0 |
| Net cash used in operating activities | -634,447 | -816,122 |
| Proceeds from sale of common stock | 15,750 | - |
| Proceeds from common stock subscription and royalty agreement | 700,000 | - |
| Payment of notes payable - related party | 0 | 7,000 |
| Payment to eidl loan | 1,226 | - |
| Proceeds from notes payable | 0 | 0 |
| Payment to economic injury disaster loan | - | 739 |
| Proceeds from notes payable - related party | 95,000 | 847,700 |
| Net cash provided by financing activities | 810,263 | 839,961 |
| Net increase in cash | 175,816 | 23,839 |
| Cash and cash equivalents at beginning of period | 88,033 | - |
| Cash and cash equivalents at end of period | 287,688 | - |
BioCorRx Inc. (BICX)
BioCorRx Inc. (BICX)